Home >> Tag Archives: Quest Diagnostics—

Tag Archives: Quest Diagnostics—

Quest to buy lab services business of Boyce and Bynum

Dec. 13, 2018—Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest ...

Read More »

Quest acquires two Texas labs, 7/17

July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.

Read More »

Quest acquires two Texas labs

June 15, 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Texas, with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty ...

Read More »

Veracyte, Quest agreement, 5/17

May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.

Read More »

HBV quantitative test, 4/17

April 2017—Quest Diagnostics launched a test service that aims to help physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus. The HBsAg qualitative test is used to aid in diagnosis of patients with HBV.

Read More »

Quest launches Zika antibody test service

Oct. 3, 2016—Quest Diagnostics has made available an antibody test service that aids the diagnosis of infection with the Zika virus. The service is based on the Zika Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay, developed by the Centers for Disease Control and Prevention and authorized for emergency use by the Food and Drug Administration. The CDC has licensed the ...

Read More »

Quest moves revenue operations to Optum

Sept. 19, 2016—Optum, a UnitedHealth Group-owned services business, will help Quest Diagnostics manage its billing and collections. The laboratory giant’s revenue services operations will become part of Optum360. These operations, including about 2,400 Quest employees, will move to Optum360 and continue to support Quest customers. This collaboration is designed to help Quest reduce the cost and complexity of its billing ...

Read More »

DiaSorin enters molecular market with Focus buy

April 7, 2016—DiaSorin will buy Quest’s Focus Diagnostics immunodiagnostic and molecular diagnostic products business for $300 million in cash. The deal includes all the tangible and intangible assets of Focus used to develop, manufacture, and distribute its molecular diagnostic products and its traditional immunoassay ELISA products, including relevant intellectual property, contracts, and customer list. Focus’ products include the Simplexa molecular ...

Read More »
X